About Pulmonary Alveolar Proteinosis
Pulmonary alveolar proteinosis is characterised by the accumulation of surfactant-derived lipoproteinaceous material in the alveoli due to impaired clearance by alveolar macrophages. The autoimmune form, caused by neutralising anti-GM-CSF autoantibodies, is the most common subtype in adults, while hereditary forms result from mutations in GM-CSF receptor genes. Whole lung lavage remains the standard of care, and GM-CSF supplementation is an emerging therapeutic strategy for autoimmune PAP.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Pulmonary Alveolar Proteinosis trials.
Anti-GM-CSF antibody titre is a key diagnostic and eligibility marker for autoimmune PAP trials; ensure serology is documented at a recognised laboratory.
Some GM-CSF therapy trials exclude patients who have undergone whole lung lavage within a defined period; check the wash-out requirement before applying.
Genetic testing to exclude hereditary PAP (CSF2RA/CSF2RB mutations) may be required before enrolment in autoimmune-specific studies.
Patient Resources
Find recruiting Pulmonary Alveolar Proteinosis trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Pulmonary Alveolar Proteinosis. Updated daily.